19 min
E28-Brolucizumab for wet AMD (HAWK and HARRIER)- Dr. Pravin Dugel The Retina Channel Podcast
-
- Medicine
Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD.
Full reference:
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017
Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD.
Full reference:
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017
19 min